A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction.
advanced ovarian cancer
interval debulking surgery
neoadjuvant chemotherapy
primary cytoreduction
propensity score
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Sep 2021
30 Sep 2021
Historique:
received:
10
08
2021
revised:
28
09
2021
accepted:
28
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Our study aims to evaluate the comparability of primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT) patients. This single-center retrospective study includes all patients treated for advanced stages high-grade serous ovarian carcinomas (HGSOC) between 2007 and 2017. Preoperative characteristics and postoperative outcomes were compared after a propensity score matching analysis. Of the 221 patients included, 38% underwent PDS, and 62% received NACT. There was no age difference at diagnosis; however, CA125 levels, PCI score levels, and rates of stage IV were higher in the NACT group. There were no differences concerning the rate and the severity of complications (
Identifiants
pubmed: 34638409
pii: cancers13194925
doi: 10.3390/cancers13194925
pmc: PMC8508489
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664
pubmed: 33028623
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942
pubmed: 33122245
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Gynecol Oncol. 2016 Mar;140(3):436-42
pubmed: 26777991
Clin Adv Hematol Oncol. 2020 Jun;18(6):332-343
pubmed: 32649655
Cancer Chemother Pharmacol. 1999;43 Suppl:S15-25
pubmed: 10357554
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:59-78
pubmed: 30306591
J Neurol Sci. 2009 Dec;287 Suppl 1:S46-9
pubmed: 20106348
Cochrane Database Syst Rev. 2021 Feb 5;2:CD005343
pubmed: 33543776
Int J Gynecol Cancer. 2019 May 2;:
pubmed: 31048403
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
BMJ. 2015 Sep 01;351:h4443
pubmed: 26328593
Am Soc Clin Oncol Educ Book. 2019 Jan;39:342-350
pubmed: 31099641
Eur J Cancer. 2018 Jan;88:31-37
pubmed: 29179135
Gynecol Oncol. 2020 Oct;159(1):239-247
pubmed: 32690392
Gynecol Oncol. 2021 Jan;160(1):24-31
pubmed: 33160693
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562443
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Curr Epidemiol Rep. 2017 Sep;4(3):211-220
pubmed: 29226065
Br J Cancer. 2014 Feb 4;110(3):551-5
pubmed: 24495873
Cochrane Database Syst Rev. 2021 Jul 30;7:CD005343
pubmed: 34328210
Int J Gynecol Cancer. 2020 Apr;30(4):436-440
pubmed: 32086362
Int J Gynecol Cancer. 2021 Feb;31(2):238-244
pubmed: 32540894
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Int J Gynecol Cancer. 2012 Oct;22(8):1337-43
pubmed: 22964527
Surgery. 1992 May;111(5):518-26
pubmed: 1598671
JAMA Oncol. 2017 Jan 1;3(1):76-82
pubmed: 27892998
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2012 Jan;124(1):10-4
pubmed: 21917306
BMC Cancer. 2014 Mar 10;14:171
pubmed: 24612526
BJOG. 2020 Oct;127(11):1409-1420
pubmed: 32285600
Am J Clin Oncol. 2018 Mar;41(3):280-285
pubmed: 26757434
Int J Cancer. 2021 Feb 1;148(3):601-608
pubmed: 32706917
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Gynecol Oncol. 2017 Mar;144(3):474-479
pubmed: 28041690
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Int J Gynecol Cancer. 2020 Jun;30(6):845-852
pubmed: 32341114
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
J Chir (Paris). 2004 Sep;141(5):277-84
pubmed: 15494657